Monday - February 02, 2026

Complement 3 Glomerulopathy Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | NovelMed Therapeutics, Apellis Pharma, Novartis, Amyndas Pharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Complement 3 Glomerulopathy pipeline constitutes 3+ key companies continuously working towards developing 3+ Complement 3 Glomerulopathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and … Continue reading

Autistic Disorder Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Jazz Pharma, Axial Therapeutics, Eli Lilly and Company, Scioto Bioscienc

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Autistic Disorder pipeline constitutes 25+ key companies continuously working towards developing 25+ Autistic Disorder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading

Alglucosidase alfa by Sanofi expected to drive market size of Glycogen Storage Disease

Explore DelveInsight’s comprehensive report on Alglucosidase alfa (Sanofi), offering detailed market insights, sales forecast, and analysis up to 2034 for strategic healthcare planning.   [Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth … Continue reading